PMID- 17879017
OWN - NLM
STAT- MEDLINE
DCOM- 20071130
LR  - 20121115
IS  - 0723-5003 (Print)
IS  - 0723-5003 (Linking)
VI  - 102
IP  - 9
DP  - 2007 Sep 15
TI  - [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
PG  - 770-7
AB  - The Philadelphia-negative chronic myeloproliferative diseases (CMPD) are very 
      complex and heterogeneous disorders. They are represented by polycythemia vera 
      (PV), chronic idiopathic myelofibrosis (CIMF), essential thrombocythemia (ET), 
      CMPD/unclassifiable (CMPD-U), chronic neutrophilic leukemia (CNL), and chronic 
      eosinophilic leukemia/hypereosinophilic syndrome (CEL/HES) according to the WHO 
      classification. Before, diagnostics were mainly focused on clinical and 
      morphological aspects, but in recent years cytogenetics and fluorescence in situ 
      hybridization (FISH) found entrance in routine schedules as chromosomal 
      abnormalities are relevant for prognosis and classification. Recently, there is 
      rapid progress in the field of molecular characterization: the JAK2V617F mutation 
      which shows a high incidence in PV, CIMF, and ET already plays a central role and 
      will probably soon be included in follow-up procedures. Due to the detection of 
      mutations in exon 12 of the JAK2 gene or mutations in the MPL gene the variety of 
      activating mutations in the CMPD is still increasing. In CEL/HES the detection of 
      the FIP1L1-PDGFRA fusion gene and overexpression of PDGFRA and PDGFRB led to 
      targeted therapy with tyrosine kinase inhibitors. Thus, diagnostics in the CMPD 
      transform toward a multimodal diagnostic concept based on a combination of 
      methods - cyto-/histomorphology, cytogenetics, and individual molecular methods 
      which can be included in a diagnostic algorithm.
FAU - Haferlach, Torsten
AU  - Haferlach T
AD  - MLL Munchner Leukamielabor GmbH, Munchen. torsen.haferlach@mll-online.com
FAU - Bacher, Ulrike
AU  - Bacher U
FAU - Kern, Wolfgang
AU  - Kern W
FAU - Schnittger, Susanne
AU  - Schnittger S
FAU - Haferlach, Claudia
AU  - Haferlach C
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Neue Erkenntnisse in der Diagnostik chronischer myeloproliferativer Syndrome: Die 
      therapeutische Relevanz steigt.
PL  - Germany
TA  - Med Klin (Munich)
JT  - Medizinische Klinik (Munich, Germany : 1983)
JID - 8303501
RN  - 0 (Receptors, Thrombopoietin)
RN  - 143641-95-6 (MPL protein, human)
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
MH  - *Algorithms
MH  - Chromosome Aberrations
MH  - Chronic Disease
MH  - Cytogenetic Analysis
MH  - DNA Mutational Analysis
MH  - Diagnosis, Differential
MH  - Gene Expression/physiology
MH  - Humans
MH  - Janus Kinase 2/genetics
MH  - Myeloproliferative Disorders/classification/*diagnosis/genetics
MH  - Receptors, Thrombopoietin/genetics
MH  - World Health Organization
RF  - 61
EDAT- 2007/09/20 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/09/20 09:00
PHST- 2006/11/15 00:00 [received]
PHST- 2007/06/11 00:00 [accepted]
PHST- 2007/09/20 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/09/20 09:00 [entrez]
AID - 10.1007/s00063-007-1094-4 [doi]
PST - ppublish
SO  - Med Klin (Munich). 2007 Sep 15;102(9):770-7. doi: 10.1007/s00063-007-1094-4.